Critical appraisal Systematic Review กิตติพนั ธุ์ ฤกษ์ เกษม ภาควิชาศัลยศาสตร์ มหาวิทยาลัยเชียงใหม่ Systematic review vs Meta-analysis • Systematic review: a systematic approach to minimising bias and error • Meta-analysis: a statistical analysis, which aim to produce a single estimate of a treatment effect • Systematic review may or may not include Meta-analysis Why do we need systematic review? • The early 1980s uncomplicated MI “Should pt receive a beta-blocker for secondary prevention before discharge?” Library: 4 randomised controlled trials (RCT) Beta-blocker vs placebo RCT 1.Mortality and hospital readmission is not different RCT 2. Not conclusive RCT 3. Beta-blocker not shown benefit RCT 4. Long term beta-blocker reduces the mortality and rate of re-infarction A review in BMJ 1981 • There is no clear evidence that betablocker improves long tem survival after MI despite almost 20 yrs of clinical trials • Good enough!! Another review in European Heart Journal 1981 “it seems perfectly reasonable to treat patients who have survived an infarction with beta-blocker” Limitation of a single study • Too small sample size false negative Problem of Conventional review • Prone to bias and error – Select only evidence support the author’s view – Not specify methodological quality of studies – Finally choose most vote ignore sample size, and design Meta-analysis = combining all available data • Attractive alternative to such large, expensive and problematic study • Weight average of the result large > small trial Meta-analysis Beta-blocker trials - MI Beta-blocker better Placebo better Cumulative meta-analysis of beta-blocker trials Cumulative meta-analysis Significant effect from 1980 onwards (OR not across 1 Meta-analysis Beta-blocker trials - MI Maybe Unnecessary trials Beta-blocker better Placebo better Benefit • Estimate the overall effect • Examine different result between studies (heterogeneity) • Identified insufficient data Cochrane collaboration • International organisation of health care profession • Promoting accessibility of systematic review • Foster development of systematic review • 50 collaborative review groups www.cochrane.org/cochrane/ccweb.htm Potentials of systematic review • Good • Bad Systematic review Basic structure and types กิตติพนั ธุ์ ฤกษ์ เกษม ภาควิชาศัลยศาสตร์ มหาวิทยาลัยเชียงใหม่ 1. Basic structure Like primary research • Why- Introduction, background • How-method • What we found-result • What it mean-discussion Basic structure • Abstract • Introduction – Background – Objectives • Method “treat a paper like a patient in 1 reseach” – – – – – – – Type of studies Inclusion criteria type of participants Exclusion criteria Type of intervention Type of outcome measures Search strategy for identification of study Method of analysis Basic structure • Result (special diagram) • Conclusion • Reference Forest plot Odd s ra tio (95% CI) Stroke rate ‘LA vs GA in carotid sx trial’ 1966-2001 % We igh t Foresell et al. 1989 0.32 (0.01,8.06) 23.2 Sbarigia et al. 1999 0.13 (0.01,2.53) 55.1 Kasprzak et al. 1999 0.37 (0.01,9.17) 21.8 Pluskwa et al. 1989 Not estimable 0.0 Prough et al. 1989 Not estimable 0.0 Binder et al. 1999 Not estimable 0.0 Overall (95% CI ) 0.22 (0.04,1.33) LA better GA better .05 .5 1 2 Odds ratio Black square = OR, horizontal line = 95% confidence interval Area of black square = weight, diamond = combined OR with 95% CI 2. types Types • Systematic review of primary research – Observational studies – Diagnostic screening – RCT 3. Method “treat a paper like a patient in 1 reseach” The process (1) • • • • • Research question Writing protocol Searching Article retrieval Literature review The process (2) • • • • Inclusion/ exclusion criteria Validity and quality of articles Data extraction/ synthesis Interpretation The question • Is local anesthesia is better than general anesthesia during carotid endarterectomy? Writing the protocol • • • • • • • • • • • Background Objectives Type of studies Inclusion criteria Type of participants Exclusion criteria Type of intervention Type of outcome measures Search strategy for identification of study Method of analysis Reference Searching • • • • Medline Other database Hand searching the literature Writing to people Getting the article • • • • Which ones to get? It takes time Libraries Inter-library Loans Literature review • You don’t have to read the whole paper yet! • Translation Validity and quality of articles • Do read the paper and see what the author thought was wrong • Unequal intervention/control size • Hidden loss to follow up Data extraction • Read method carefully • Design a form Synthesis/ Interpretation • Estimates and confidence intervals pool effect make by statistic method e.g. Peto method (fix method) give more weight effect for large study than small study (P value) • Difference between studies (Heterogeneity) Chi-squared test (P value) Small RCTs show LA is marginal lower mortality than GA Local Study or Subgroup General Peto Odds Ratio Events Total Events Total Weight Peto, Fixed, 95% CI Binder 1999 0 27 0 19 Forssell 1989 0 56 1 55 14.5% 0.13 [0.00, 6.70] Kasprzak 2006 0 91 1 95 14.5% 0.14 [0.00, 7.12] McCarthy 2001a 1 34 1 33 28.5% 0.97 [0.06, 15.85] Pluskwa 1989 0 10 0 10 Not estimable Prough 1989 0 13 0 10 Not estimable Sbarigia 1999 0 55 3 52 Total (95% CI) Total events 286 1 Peto, Fixed, 95% CI Not estimable 42.6% 0.12 [0.01, 1.21] 274 100.0% 0.23 [0.05, 1.01] 6 Heterogeneity: Chi² = 1.44, df = 3 (P = 0.70); I² = 0% Test for overall effect: Z = 1.94 (P = 0.05) Peto Odds Ratio 0.1 0.2 0.5 1 2 5 10 Local better General better Critical Appraisal 1. Are the result valid? 2. What are the results? 1. Are the result valid? • Did this review address a sensible clinical question • Was the search for relavant studies detailed and exhaustive? • Were selection and assessment of studies reproducible? • Were the primary studies of high methodological quality? Publication bias “A (significant) beneficial treatment effect are published, but an equal result remain unpublished” • In general medical journal and public heath journal reported statistically significant 85.4% • In psychological journal 95.6% Time lag bias • “Positive result will dominate the literature for several year until the negative will report later” • HIV trial in USA, median time to publish of positive result 4.2 years, but negative result 6.4 years Duplicate publication bias • “ one study presents and reports several times” “ include this lead to overestimation of treatment effect” • Ondersetron to prevent postoperative nausea vomitting 16 studies 3 duplicated papers • Sometimes difficult to say, since not share single common authors !!!!!! Language bias • “Authors tend to report positive result in international papers, English language journal, but if negative result are published in local journal” Outcome reporting bias • In trials many outcome is recorded but only favorable finding will be reported • Clinical trials by drug companies, unpublished trials gave information on adverse effect > published trials Selection Bias • Tend to happen in non Randomised controlled trials (non RCT) • For example select low risk group to new treatment group 2. What are the result? • Were the results similar from study to study? If yes, the credit of single estimates is OK. – Point estimates similar? – Overlapping confidence interval – Test for heterogeneity? (Chi square test) – Percentage of variability (I2 ) good < 20%, concern 20-50%,serious concern > 50% Local Study or Subgroup General Events Total Events Peto Odds Ratio Total Weight Agrifoglio 1987 0 29 2 28 1.5% Allen 1994 2 274 4 310 4.4% 0.58 [0.12, 2.89] Andersen 1980 6 179 1 152 5.1% 3.66 [0.82, 16.41] Bartoloni 1991 0 69 0 75 Becquemin 1991 1 132 6 220 4.8% 0.37 [0.08, 1.71] Bowyer 2000 2 272 2 228 3.0% 0.84 [0.12, 6.02] Brown 1999 0 157 0 132 Calligaro 2001 3 185 4 216 5.1% 0.87 [0.20, 3.91] Corson 1987 1 145 3 223 2.8% 0.54 [0.07, 4.08] ECST 1998 0 58 17 1681 1.6% 0.35 [0.02, 5.03] Gabelman 1983 0 48 1 40 0.7% 0.11 [0.00, 5.68] Ghali 1997 0 33 0 57 Not estimable Godin 1989 0 50 0 50 Not estimable Gurer 2003 1 200 2 165 2.2% 0.42 [0.04, 4.09] Harbaugh 2000 2 632 0 171 1.0% 3.57 [0.12, 105.59] 2 116 1 118 2.2% 1.99 [0.21, 19.35] 47 3382 12 593 22.2% 0.65 [0.32, 1.33] Hartsell 1999 Imparato 1998 Not estimable Not estimable 0 50 0 30 Kalko 2007 2 306 3 127 3.1% 0.22 [0.03, 1.55] Kraiss 1995 0 18 1 178 0.3% 0.33 [0.00, 294.58] Kucey 1998 0 185 23 1096 8.4% 0.30 [0.09, 0.98] Love 2000 0 200 3 243 2.2% 0.16 [0.02, 1.56] Marrocco 2004 0 50 0 63 McCarthy 2001b 2 100 0 140 1.5% 11.13 [0.67, 186.25] McCleary 1996 1 32 0 33 0.8% 7.62 [0.15, 384.38] Mertens 2000 0 22 0 72 Mofidi 2006 1 192 3 179 3.0% 0.34 [0.05, 2.43] Muskett 1986 0 30 0 45 NASCET 1998 0 104 14 1310 2.8% 0.34 [0.04, 2.53] Ombrellaro 1996 0 140 0 126 Palmer 1989 2 184 0 37 0.8% 3.34 [0.08, 137.98] Quigley 2000 0 126 1 78 0.7% 0.07 [0.00, 4.13] Reina 1998 3 116 3 188 4.2% 1.67 [0.32, 8.77] Rignano 1999 0 76 1 169 0.6% 0.23 [0.00, 16.24] Santamaria 2004 0 203 2 56 1.0% 0.01 [0.00, 0.28] Schwartz 1988 0 149 2 162 1.5% 0.15 [0.01, 2.35] Shah 1994 5 654 3 219 4.5% 0.51 [0.10, 2.56] Sternbach 2002 2 226 1 324 2.2% 2.89 [0.29, 28.92] Stone 2000 0 67 0 61 Stoughton 1998 0 150 0 58 Syrek 1999 1 83 0 26 0.5% 3.72 [0.04, 369.48] Taylor 1999 2 140 16 1152 5.2% 1.03 [0.23, 4.60] 10631 100.0% 0.63 [0.45, 0.89] Total events 9564 88 Look overlapping confidence interval Not estimable Not estimable Not estimable Not estimable Not estimable Not estimable Not estimable Rerkasem Cochrane Database Syst Rev 2008; (4):CD000126. 131 Heterogeneity: Chi² = 33.76, df = 30 (P = 0.29); I² = 11% Test for overall effect: Z = 2.65 (P = 0.008) Peto, Fixed, 95% CI 0.13 [0.01, 2.06] Jopling 1983 Total (95% CI) Peto Odds Ratio Peto, Fixed, 95% CI 0.1 0.2 0.5 1 2 5 Local better General better 10 Small RCTs show LA is marginal lower mortality than GA Local Study or Subgroup General Peto Odds Ratio Events Total Events Total Weight Peto, Fixed, 95% CI Binder 1999 0 27 0 19 Forssell 1989 0 56 1 55 14.5% 0.13 [0.00, 6.70] Kasprzak 2006 0 91 1 95 14.5% 0.14 [0.00, 7.12] McCarthy 2001a 1 34 1 33 28.5% 0.97 [0.06, 15.85] Pluskwa 1989 0 10 0 10 Not estimable Prough 1989 0 13 0 10 Not estimable Sbarigia 1999 0 55 3 52 Total (95% CI) Total events 286 1 Peto, Fixed, 95% CI Not estimable 42.6% 0.12 [0.01, 1.21] 274 100.0% 0.23 [0.05, 1.01] 6 Heterogeneity: Chi² = 1.44, df = 3 (P = 0.70); I² = 0% Test for overall effect: Z = 1.94 (P = 0.05) Peto Odds Ratio 0.1 0.2 0.5 1 2 5 10 Local better General better Rerkasem Cochrane Database Syst Rev 2008 (4):CD000126. 2. What are the result? • Were the results similar from study to study? • What are the overall results of the reviews? • How precise were the results?